- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Milken Institute's Sarah Wells Kocsis Highlights Key Findings of Her Research on CKD
Sarah Wells Kocsis, MBA, is co-author of the Milken Institute report, “Chronic Kidney Disease: Finding a Path to Prevention, Earlier Detection, and Management.” She spoke to The American Journal of Managed Care® about the findings of the report and how they can be incorporated into care for patients with chronic kidney disease (CKD).
Sarah Wells Kocsis, MBA, director of the Center for Public Health at the Milken Institute, talks about the key findings of her recently authored report, “Chronic Kidney Disease: Finding a Path to Prevention, Earlier Detection, and Management.”
Transcript
What are the biggest takeaways of your research?
Chronic kidney disease [CKD] is a huge public health problem. It's intricately tied to health equity and social determinants of health. So tackling CKD is going to require a major shift in our mindset and the approach. Roughly 1 in 7 adults have chronic kidney disease, and 9 out of 10 of them don't even know that they have it, so we really need to listen to what the research is telling us. And what it's telling us is that we really need to focus right now on root causes, and these causes are structural, social, and health related. That's going to require practical, scalable, equitable solutions aimed at both detecting and managing the condition upstream at earlier stages and focusing on reducing the burden of this debilitating disease.
Nomogram Aids Early Detection of Myasthenic Crisis Risk
August 19th 2025Despite nurses often being the first health care workers many patients encounter, they frequently lack adequate tools to optimally evaluate their patients’ conditions, as in the case with myasthenia gravis and being able to predict patients at risk of myasthenic crisis.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Switching to Gene Therapy After Nusinersen or Risdiplam May Benefit Patients With SMA
August 15th 2025Children with spinal muscular atrophy (SMA) showed motor function improvements after switching to onasemnogene abeparvovec following prior treatment with nusinersen or risdiplam in a real-world study.
Read More
